VEGF靶向药导致肾脏毒性的机制研究进展  

Progress in the mechanism of renal toxicity induced by VEGF-targeting drugs

作　　者：周佳琪(综述) 梁伟峰[1,2] (审校) ZHOU Jia-qi;LIANG Wei-feng(State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,the First Affiliated Hospital of College of Medicine of Zhejiang University,Hangzhou 310013,Zhejiang,CHINA;Dr.kang International Medical Center,Hangzhou 311215,Zhejiang,CHINA)

机构地区：[1]浙江大学医学院附属第一医院传染病诊治国家重点实验室国家感染性疾病临床医学研究中心感染性疾病诊治协同创新中心,浙江杭州310013 [2]康大夫国际医院,浙江杭州311215

出　　处：《海南医学》2020年第2期231-235,共5页Hainan Medical Journal

基　　金：国家“十三五“重大专项(编号:2017ZX10203202-003)

摘　　要：血管内皮生长因子(VEGF)靶向药是目前最常用的抗肿瘤靶向药,在肾癌、结肠癌等肿瘤中被广泛使用,主要分为单抗类、VEGF融合肽和酪氨酸激酶抑制剂(TKI)三类。虽然VEGF靶向药对许多肿瘤都有治疗效果,但是很多报道证实其治疗的同时伴有肾毒性作用。血栓性微血管病变(TMA)和微小病变性肾病(MCD)/局灶节段性肾小球硬化(FSGS)是最常见的两类病理类型。本文将讨论VEGF靶向药导致两类病理类型的机制。Vascular endothelial growth factor(VEGF)-targeted anti-cancer drugs are currently most used in the targeted anti-cancer therapy, and widely used in tumors such as kidney cancer and colon cancer. VEGF-targeted drugs are mainly divided into three classes: anti-VEGF monoclonal antibody, VEGF trap and tyrosine kinase inhibitor(TKI).Although VEGF-targeted drugs have achieved the promising results, renal toxicity has been confirmed many times in related studies. Thrombotic microangiopathy(TMA) and minimally diseased nephropathy(MCD)/focal segmental glomerulosclerosis(FSGS) are the two most common types of pathology. This article would review the mechanism by which VEGF-targeted drugs cause two types of pathology.

关 键 词：血管内皮生长因子 肾毒性 RELA c-maf诱导蛋白 

分 类 号：R979.1[医药卫生—药品]